What's Happening?
Amoéba, a greentech company based in Chassieu, France, has been awarded the gold medal at the SIVAL Innovation 2026 Competition for its biocontrol solution, AXPERA. The award was presented during the International Exhibition of Plant Production Techniques
in Angers, France. Amoéba's solution, which focuses on sustainable protection against fungal diseases, was recognized in the 'plant health, soil and growing media' category. The company, in partnership with Koppert, plans to commercially launch its biocontrol solution for vineyards and vegetable crops in 2026, pending market authorizations in targeted European countries. The solution has already received market authorization in the United States. Amoéba's CEO, Jean-François Doucet, expressed pride in the recognition and emphasized the company's commitment to providing effective alternatives to chemical products in agriculture.
Why It's Important?
The recognition of Amoéba's biocontrol solution at SIVAL highlights the growing importance of sustainable agricultural practices. As regulatory pressures increase to reduce the use of chemical pesticides, solutions like AXPERA offer a viable alternative for farmers, particularly in the wine-growing and vegetable sectors. The successful launch and adoption of such biocontrol solutions could significantly impact the agricultural industry by reducing reliance on harmful chemicals, thus promoting environmental sustainability. This development is crucial for the U.S. market, where the solution has already been authorized, potentially leading to increased adoption of eco-friendly agricultural practices.
What's Next?
Amoéba is awaiting marketing authorizations for its TIAGAN solution, formerly known as AXPERA, in nine European countries, with decisions expected in the first half of 2026. The company is working closely with Koppert to strategize the marketing of TIAGAN, particularly in France and Italy, where there is a high demand for alternatives to copper-based fungicides. Amoéba is also investing in its production capabilities to prepare for a commercial ramp-up. The company aims to establish a robust supply chain to meet the anticipated demand for its biocontrol solution in the coming year.
